Background: Sickle cell anemia (SCA) is amongst the most common genetic condition. It is the mutation of beta globin chain and has been acknowledged to have a global public health impact. This disease is common among many tribal and backward populations in India. In the central India its prevalence varies from 10-40%. It can be classified as two types of homozygous sickle cell disease and heterozygous sickle cell trait. Hand-foot syndrome (swelling), pain and anemia are some of the very common complications of the disease. In Sickle cell anemia, the number of healthy RBCs decrease which results in reduction of Oxygen in the tissues.Objectives: Currently available drugs do not seem to improve hemoglobin level of patients of Sickle cell anemia to considerable extent. Our experience with Hemoxin R Plus, an Ayurvedic medicine was very encouraging in improving quality of Life of SCA patients. Our aim of this analysis of the data available with us was to compare safety and efficacy of Hemoxin R Plus, with the standard of care in improving hemoglobin, RBC and Quality of life and in patients having SCA.Materials and Methods: This was a retrospective analysis. Hospital records of the patients were used and reviewed for the analysis. Data was collected by the doctors from the medical records department, who treated the patients. Data analysis was done by applying Levene's Test for Equality of Variances. Results: Hemoxin R Plus was found to be better than the standard of care (hydroxyurea and folic acid) for every parameter considered for analysis, viz. Hemoglobin, RBCs and Sr. Creatinine. Hemoxin R Plus was found to be safe in the dose administered, as there were no adverse events reported, and liver markers and Sr. Creatinine did not go higher for any patient.Conclusion: Capsule Hemoxin R Plus can be used for of the management of sickle cell anemia in improving hemoglobin, RBCs and in reducing pain and inimproving the quality of life.